Floatz logo

Epstein-Barr Virus Specific T-Lymphocytes

Epstein-Barr Virus Infections

Jessie L. AlexanderPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Epstein-Barr Virus Infections cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Jennifer Amengual
Phase 2BB
L-Dep
Beijing Friendship Hospital
Phase 3B
Bortezomib
Massachusetts General Hospital
Phase 2B
Tabelecleucel
Pierre Fabre Medicament
Phase 2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC

View all 16 →

Same molecule, other indications

Epstein-Barr Virus Specific T-Lymphocytes is also rated in:

adenoviridae infectious diseaseDormant
CCC
Indicative ·
48 / 100
View asset →
cytomegalovirus infectionDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →